Sorrento Therapeutics, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Sorrento Therapeutics, Inc. (SRNEQ) is a clinical-stage biopharmaceutical company that discovers, develops, and seeks to commercialize proprietary therapies addressing unmet needs in oncology, pain management, autoimmune disorders, infectious diseases, and inflammation. Founded in 2006 and headquartered in San Diego, California, the company leverages proprietary platforms including its G-MAB antibody library, antibody-drug conjugates (ADCs), CAR-T cell therapies, bispecific antibodies, and small-molecule inhibitors to advance a diversified pipeline; key candidates encompass resiniferatoxin (RTX) for non-opioid cancer and osteoarthritis pain, Cynviloq (next-generation oncolytic paclitaxel), STI-6129 (CD38-targeted ADC for multiple myeloma), STI-1558 (SARS-CoV-2 protease inhibitor), abivertinib (BTK inhibitor), ZTlido lidocaine patch, and cell therapy approaches like CAR-TNK and exosome-based products. It operates research and development facilities in North America and Asia, with products derived from fully human monoclonal antibodies, targeted delivery modalities such as lymphoseek for immunotherapy, and non-opioid neurotoxin formulations targeting global markets in cancer therapeutics, chronic pain, and viral indications. In recent major developments, Sorrento filed for Chapter 11 bankruptcy on February 13, 2023, followed by court approval of a Chapter 11 liquidation plan on November 30, 2023, leading to delisting from Nasdaq and trading on OTC Markets as SRNEQ with delinquent SEC reporting; its majority-owned subsidiary Scilex Holding Company pursued a business combination with VCKA in 2022 to list on Nasdaq as SCLX, separating non-opioid pain assets like ZTlido, while ongoing pipeline efforts include Phase 3 trials for dexamethasone in sciatica and STI-1558 in COVID-19 as of 2024-2025.
Reviewing SQZ Biotechnologies (NYSE:SQZ) and Sorrento Therapeutics (OTCMKTS:SRNEQ)
Sorrento Therapeutics (OTCMKTS:SRNEQ) versus LadRx (OTCMKTS:CYTR) Financial Contrast
Contrasting Sorrento Therapeutics (OTCMKTS:SRNEQ) and LadRx (OTCMKTS:CYTR)
Sorrento Therapeutics (OTCMKTS:SRNEQ) and bluebird bio (NASDAQ:BLUE) Financial Comparison
Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders
3 Penny Stocks to Make You the Millionaire Next Door